임상시험 시장 : 시장 규모, 점유율 및 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of clinical trials Market

The global clinical trials market plays a foundational role in the development of new pharmaceuticals, biologics, and medical devices by evaluating their safety, efficacy, and therapeutic value. In 2025, the global clinical trials market size was valued at USD 64.94 billion, reflecting strong demand from pharmaceutical, biotechnology, and medical device companies. The market is projected to grow to USD 69.27 billion in 2026 and further expand to USD 120.75 billion by 2034, highlighting the increasing importance of clinical research in modern healthcare innovation.

Clinical trials are conducted across multiple phases and therapeutic areas to support regulatory approvals and commercialization of novel treatments. Rising investments in research and development, increasing prevalence of chronic diseases, and growing reliance on Contract Research Organizations (CROs) are key factors contributing to market expansion. Major companies such as IQVIA Inc., Laboratory Corporation of America Holdings, and Pfizer Inc. are actively leveraging advanced technologies to improve trial efficiency and data quality.

Market Dynamics

Market Drivers

The rising global burden of chronic diseases, including cancer, diabetes, cardiovascular disorders, and neurological conditions, is a major driver for the clinical trials market. The need for innovative and effective therapeutics has significantly increased the number of clinical studies conducted worldwide. Additionally, the growing volume of clinical trials-supported by expanding pharmaceutical pipelines-continues to fuel market growth.

Market Restraints

Despite strong demand, the market faces constraints related to the limited availability of skilled professionals and the high cost of conducting clinical studies. Clinical trial execution requires experienced researchers, clinicians, and regulatory experts, and shortages in qualified personnel can delay timelines. Furthermore, regulatory compliance, complex study protocols, and low success rates increase overall development costs, restraining market expansion.

Market Opportunities

Increasing outsourcing of clinical research to CROs presents a major growth opportunity. Pharmaceutical and biotechnology companies are partnering with CROs to reduce operational costs, access specialized expertise, and accelerate trial timelines. This trend is particularly beneficial for small and mid-sized companies lacking in-house research infrastructure.

Market Challenges

Patient recruitment and retention remain significant challenges, often leading to extended study durations and cost overruns. Regulatory variability across regions and strict ethical requirements related to data privacy and informed consent also add complexity to clinical trial execution.

Market Trends

One of the most prominent trends in the clinical trials market is the increasing investment in R&D by pharmaceutical and biotechnological companies. The integration of artificial intelligence (AI) and advanced data analytics is transforming trial design, patient recruitment, and data interpretation. Additionally, decentralized clinical trials (DCTs) are gaining traction, enabling remote participation through digital health technologies and improving patient accessibility.

Emerging markets such as China and India are also becoming attractive destinations for clinical research due to diverse patient populations, cost advantages, and supportive regulatory reforms.

Segmentation Analysis

By phase, Phase III clinical trials dominate the market due to their large scale, high investment requirements, and increasing outsourcing to CROs. By application, oncology holds the largest share, driven by the growing prevalence of cancer and the need for targeted therapies. CNS disorders and metabolic diseases are also witnessing strong growth due to rising disease incidence.

Regional Outlook

North America dominated the clinical trials market with a 43.90% share in 2025, supported by high R&D expenditure, strong CRO presence, and advanced research infrastructure. The U.S. remains the largest contributor within the region. Europe follows with steady growth driven by pharmaceutical R&D investments, while Asia Pacific is the fastest-growing region due to increasing clinical activity in China, India, and Japan. Latin America and the Middle East & Africa are emerging as cost-effective regions for conducting clinical studies.

Competitive Landscape

The market is moderately consolidated, with leading CROs and service providers focusing on service expansion, digital transformation, and strategic partnerships. Key players include IQVIA Inc., ICON plc, and Syneos Health. These companies emphasize technology-driven platforms, decentralized trials, and global site networks to strengthen their market position.

Report Coverage

The clinical trials market report delivers a comprehensive assessment of market size, growth drivers, restraints, opportunities, trends, segmentation, regional outlook, competitive landscape, and key industry developments. The analysis strictly evaluates market performance for 2025, 2026, and 2034, providing both qualitative and quantitative insights into how innovation, outsourcing, and global R&D investments are shaping the future of the clinical trials industry.

Conclusion

The global clinical trials market is positioned for steady and sustained growth, driven by the increasing need for innovative therapies, expanding pharmaceutical and biotechnology pipelines, and rising global disease burden. With the market valued at USD 64.94 billion in 2025, its progression to USD 69.27 billion in 2026 reflects continued investment in research activities and greater reliance on structured clinical development pathways. The long-term expansion to USD 120.75 billion by 2034 underscores the critical role clinical trials play in bringing safe and effective drugs, biologics, and medical devices to market.

Key growth enablers include higher R&D spending, greater outsourcing to Contract Research Organizations, adoption of advanced technologies such as artificial intelligence and decentralized trial models, and expanding clinical activity in emerging regions. While challenges such as high trial costs, skilled workforce shortages, regulatory complexity, and patient recruitment issues persist, ongoing innovation and process optimization by leading players such as IQVIA Inc., ICON plc, and Syneos Health are helping to mitigate these barriers.

Overall, evaluated strictly for 2025, 2026, and 2034, the clinical trials market remains a cornerstone of global healthcare innovation, enabling scientific advancement, regulatory approvals, and the development of next-generation treatments across diverse therapeutic areas.

Segmentation By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

By Application

• Oncology
• CNS Disorder
• Cardiology
• Infectious Disease
• Metabolic Disorder
• Renal/Nephrology
• Others

By Region

• North America (By Phase, By Application, and By Country)
  • U.S.
  • Canada
• Europe (By Phase, By Application, and By Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific ( By Phase, By Application, and By Country/Sub-Region)
  • China
  • India
  • Japan
  • Australia
  • Southeast Asia
  • Rest of the Asia Pacific
• Rest of the World (By Phase, By Application)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Number of Clinical Trials - by Key Countries, 2025
• 4.2. R&D expenditures, by Key Players
• 4.3. New Clinical Trials Initiatives, by Key Countries
• 4.4. Key Industry Developments (Mergers, Partnerships, Acquisitions, etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Phase
  • 5.1.1. Phase I
  • 5.1.2. Phase II
  • 5.1.3. Phase III
  • 5.1.4. Phase IV
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Oncology
  • 5.2.2. CNS Disorder
  • 5.2.3. Cardiology
  • 5.2.4. Infectious Disease
  • 5.2.5. Metabolic Disorder
  • 5.2.6. Renal/Nephrology
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Rest of the World

6. North America Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Phase
  • 6.1.1. Phase I
  • 6.1.2. Phase II
  • 6.1.3. Phase III
  • 6.1.4. Phase IV
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Oncology
  • 6.2.2. CNS Disorder
  • 6.2.3. Cardiology
  • 6.2.4. Infectious Disease
  • 6.2.5. Metabolic Disorder
  • 6.2.6. Renal/Nephrology
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Phase
  • 7.1.1. Phase I
  • 7.1.2. Phase II
  • 7.1.3. Phase III
  • 7.1.4. Phase IV
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Oncology
  • 7.2.2. CNS Disorder
  • 7.2.3. Cardiology
  • 7.2.4. Infectious Disease
  • 7.2.5. Metabolic Disorder
  • 7.2.6. Renal/Nephrology
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 7.3.1. Germany
  • 7.3.2. U.K.
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia Pacific Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Phase
  • 8.1.1. Phase I
  • 8.1.2. Phase II
  • 8.1.3. Phase III
  • 8.1.4. Phase IV
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Oncology
  • 8.2.2. CNS Disorder
  • 8.2.3. Cardiology
  • 8.2.4. Infectious Disease
  • 8.2.5. Metabolic Disorder
  • 8.2.6. Renal/Nephrology
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Rest of the World Clinical Trials Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Phase
  • 9.1.1. Phase I
  • 9.1.2. Phase II
  • 9.1.3. Phase III
  • 9.1.4. Phase IV
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Oncology
  • 9.2.2. CNS Disorder
  • 9.2.3. Cardiology
  • 9.2.4. Infectious Disease
  • 9.2.5. Metabolic Disorder
  • 9.2.6. Renal/Nephrology
  • 9.2.7. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. IQVIA Inc.
    • 10.2.1.1. Overview
    • 10.2.1.2. Services
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Laboratory Corporation of America Holdings
    • 10.2.2.1. Overview
    • 10.2.2.2. Services
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Thermo Fisher Scientific Inc.
    • 10.2.3.1. Overview
    • 10.2.3.2. Services
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Parexel International Corporation
    • 10.2.4.1. Overview
    • 10.2.4.2. Services
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. Medpace Holdings, Inc.
    • 10.2.5.1. Overview
    • 10.2.5.2. Services
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Icon plc
    • 10.2.6.1. Overview
    • 10.2.6.2. Services
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Syneos Health
    • 10.2.7.1. Overview
    • 10.2.7.2. Services
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. WuXi AppTec
    • 10.2.8.1. Overview
    • 10.2.8.2. Services
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. Charles River Laboratories
    • 10.2.9.1. Overview
    • 10.2.9.2. Services
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)
  • 10.2.10. Pfizer Inc.
    • 10.2.10.1. Overview
    • 10.2.10.2. Services
    • 10.2.10.3. SWOT Analysis
    • 10.2.10.4. Recent Developments
    • 10.2.10.5. Strategies
    • 10.2.10.6. Financials (Based on Availability)
  • 10.2.11. Lilly
    • 10.2.11.1. Overview
    • 10.2.11.2. Services
    • 10.2.11.3. SWOT Analysis
    • 10.2.11.4. Recent Developments
    • 10.2.11.5. Strategies
    • 10.2.11.6. Financials (Based on Availability)